

Title (en)

N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS

Title (de)

N-ALKYL-AZACYCLOALKYL-NMDA/NR2B-ANTAGONISTEN

Title (fr)

ANTAGONISTES DE NMDA/NR2B A BASE DE N-ALKYL-AZACYCLOALKYLE

Publication

**EP 1874318 A2 20080109 (EN)**

Application

**EP 06750229 A 20060414**

Priority

- US 2006014139 W 20060414
- US 67263905 P 20050419

Abstract (en)

[origin: WO2006113471A2] Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke.

IPC 8 full level

**A61K 31/55** (2006.01)

CPC (source: EP)

**A61P 3/10** (2017.12); **A61P 19/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/02** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/16** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 31/18** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07D 487/04** (2013.01)

Citation (search report)

See references of WO 2006113471A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

**WO 2006113471 A2 20061026; WO 2006113471 A3 20071213**; AU 2006236625 A1 20061026; CA 2603876 A1 20061026; CN 101163482 A 20080416; EP 1874318 A2 20080109; JP 2008536927 A 20080911

DOCDB simple family (application)

**US 2006014139 W 20060414**; AU 2006236625 A 20060414; CA 2603876 A 20060414; CN 200680012726 A 20060414; EP 06750229 A 20060414; JP 2008507751 A 20060414